专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

EP2854846B1 IMMUNOGENIC COMPOUNDS COMPRISING HIV GP41 PEPTIDE COUPLED TO CRM197 CARRIER PROTEIN 有权
公开(公告)号：EP2854846B1
公开(公告)日：2018-09-12
申请号：EP13737420.3
申请日：2013-05-30
申请人： Minka Therapeutics
发明人： CROUZET, Joël , HO TSONG FANG, Raphaël , DESFONTAINES, Dominique
IPC分类号： A61K39/21 , A61P31/18
CPC分类号： A61K39/21 , A61K39/12 , A61K47/6415 , A61K2039/53 , A61K2039/55505 , A61K2039/6037 , A61K2039/6081 , A61K2039/627 , C07K16/1063 , C12N7/00 , C12N2740/16134
摘要： The present invention relates to the field of vaccines directed against viruses of the HIV family. More particularly, it relates to an immunogenic compound comprising a peptide of the following formula (I) €ƒ€ƒ€ƒ€ƒ€ƒ€ƒ€ƒ€ƒ NH 2 - [Nt] y -P-W-N-X 1 -S- X 2 -S-N-X 3 -X 4 -X 5 -X 6 -X 7 -I-W-[Ct] z -COOH€ƒ€ƒ€ƒ€ƒ€ƒ(I) which is covalently linked to a carrier protein consisting of a CRM197 protein. It also concerns a composition containing this immunogenic compound and the uses of these immunogenic compounds and compositions for preventing and/or treating a condition caused by the infection of an individual with a HIV virus.

2. 发明授权

EP2358757B1 ANTIVIRAL VACCINES WITH IMPROVED CELLULAR IMMUNOGENICITY 有权
公开(公告)号：EP2358757B1
公开(公告)日：2018-09-12
申请号：EP09828172.8
申请日：2009-11-18
申请人： Beth Israel Deaconess Medical Center , Los Alamos National Security, LLC
发明人： BAROUCH, Dan, H. , KORBER, Bette, T. , FISCHER, William, M.
IPC分类号： C07K17/00 , C07K14/005 , A61K39/12 , A61K39/235 , A61K39/21 , A61K39/275 , A61K39/00 , C12N7/00
CPC分类号： A61K39/21 , A61K39/12 , A61K39/235 , A61K39/275 , A61K2039/53 , C07K14/005 , C12N7/00 , C12N2710/10043 , C12N2710/10343 , C12N2710/24043 , C12N2740/16122 , C12N2740/16134 , C12N2740/16171 , C12N2740/16222 , C12N2740/16234 , C12N2740/16271 , C12N2740/16322 , C12N2740/16334 , Y02A50/467
摘要： The invention provides compositions, methods, and kits for the treatment or prevention of viral infections. The polyvalent (e.g., 2-valent) vaccines described herein incorporate computationally-optimized viral polypeptides that can increase the diversity or breadth and depth of cellular immune response in vaccinated subjects.

3. 发明公开

EP3352789A1 CROSS-REACTIVE T-CELL EPITOPES OF HIV, SIV, AND FIV FOR VACCINES IN HUMANS AND CATS 审中-公开
公开(公告)号：EP3352789A1
公开(公告)日：2018-08-01
申请号：EP16849829.3
申请日：2016-09-25
申请人： University of Florida Research Foundation, Inc.
发明人： YAMAMOTO, Janet, K.
IPC分类号： A61K39/12 , A61K39/395 , A61K39/00
CPC分类号： A61K39/21 , A61K9/0019 , A61K39/12 , A61K2039/5252 , A61K2039/54 , A61K2039/545 , A61K2039/552 , A61K2039/572 , A61K2039/575 , A61K2039/645 , A61P31/14 , A61P31/18 , C07K14/005 , C12N2740/15034 , C12N2740/15071 , C12N2740/16134 , C12N2740/16171 , C12N2740/16234 , C12N2740/16271 , C12N2740/16334 , C12N2740/16371
摘要： The subject invention concerns methods and materials for inducing an immune response in an animal or person against an immunodeficiency virus, such as HIV, SIV, or FIV. In one embodiment, a method of the invention comprises administering one or more antigens and/or immunogens to the person or animal wherein the antigen and/or immunogen comprises one or more evolutionarily conserved epitopes of immunodeficiency viruses. In one embodiment, the epitope is one that is conserved between HIV and FIV.

4. 发明公开

EP3273990A1 ENGINEERED AND MULTIMERIZED HUMAN IMMUNODEFICIENCY VIRUS ENVELOPE GLYCOPROTEINS AND USES THEREOF 审中-公开
标题翻译：工程化和多重化的人免疫缺陷病毒包膜糖蛋白及其应用
公开(公告)号：EP3273990A1
公开(公告)日：2018-01-31
申请号：EP16769681.4
申请日：2016-03-24
申请人： Fred Hutchinson Cancer Research Center
发明人： STRONG, Roland K. , CORRENTI, Colin , STAMATATOS, Leonidas , MCGUIRE, Andrew
IPC分类号： A61K39/21 , C07K14/155 , C12N15/00 , C12N15/49 , C12N15/63
CPC分类号： A61K39/21 , A61K39/12 , A61P31/18 , C07K14/005 , C07K14/16 , C12N2740/16034 , C12N2740/16122 , C12N2740/16134
摘要： Multimerized human immunodeficiency virus (HIV) envelope glycoproteins are described. The envelope glycoproteins are multimerized Engineered and multimerized human immunodeficiency virus (HIV) envelope glycoproteins are described. The envelope glycoproteins can be multimerized using a heptamerization domain such as a C4b binding protein multimerization domain or a ferritin fusion. The engineered and multimerized envelope glycoproteins can derived from glycoprotein 120 (gp120) and can used as an HIV vaccine.

5. 发明公开

EP3266448A1 MICROPARTICULATED VACCINES FOR THE ORAL OR NASAL VACCINATION AND BOOSTERING OF ANIMALS INCLUDING FISH 审中-公开
标题翻译：用于口服或鼻腔接种和包括鱼在内的动物促进增殖的微粒疫苗
公开(公告)号：EP3266448A1
公开(公告)日：2018-01-10
申请号：EP17184278.4
申请日：2010-03-26
申请人： Intervet International B.V.
发明人： HAREL, Moti , CARPENTER, Brian
IPC分类号： A61K9/20 , A61K47/36 , A61K9/16 , A61K9/28 , A61P37/00 , A61P31/00 , A61K39/205
CPC分类号： A61K39/39 , A61K9/0043 , A61K9/006 , A61K9/5015 , A61K39/00 , A61K39/0208 , A61K39/0233 , A61K39/0241 , A61K39/12 , A61K39/145 , A61K39/21 , A61K2039/522 , A61K2039/5254 , A61K2039/5258 , A61K2039/541 , A61K2039/542 , A61K2039/543 , A61K2039/552 , A61K2039/55555 , A61K2039/55583 , C12N7/00 , C12N2720/10011 , C12N2720/10023 , C12N2720/10034 , C12N2740/10011 , C12N2740/10034 , C12N2760/10034 , C12N2760/16011 , C12N2760/16022 , C12N2760/16034
摘要： The invention relates to a composition and a method for manufacturing semi-dry or dry particles containing a mucoadhesive polymer and a bioactive agent such as an immunogenic substance (e.g., a vaccine), that allows the oral or nasal administration and delivery of the bioactive agent essentially unaltered to mucosal surfaces in an animal, including an aquatic animal.
摘要翻译：本发明涉及用于制造含有粘膜粘附聚合物和生物活性剂（例如免疫原性物质（例如疫苗））的半干或干颗粒的组合物和方法，其允许口服或经鼻施用和递送生物活性剂基本上不会改变动物包括水生动物的粘膜表面。

6. 发明公开

EP3209784A1 DNA MOTIF COMPOUNDS AND METHODS FOR INDUCING SPECIFIC ANTIBODIES AND CELLULAR IMMUNITY 审中-公开
标题翻译： DNA MOTIF化合物和诱导特异性抗体和细胞免疫的方法
公开(公告)号：EP3209784A1
公开(公告)日：2017-08-30
申请号：EP15852067.6
申请日：2015-10-26
申请人： Versitech Limited , Nanjing University
发明人： CHEN, Zhiwei , WU, Xilin , WU, Zhiwei
IPC分类号： C12N15/85 , C12N15/49
CPC分类号： A61K39/21 , A61K39/12 , A61K2039/53 , A61K2039/575 , C12N2740/16034 , C12N2740/16234
摘要： The present invention relates to the field of applied immunotechnology and medicine. More specifically, it relates to DNA motif vaccine design, glyco-DNA motif vaccine design, and immunogen design for producing antibodies against an epitope of arbitrary sequences or polysaccharide epitope, particularly those epitopes against which it is otherwise very difficult to induce antibodies, such as those of HIV-1. The present invention also relates to immunogen design to induce robust cellular and humoral immunity.
摘要翻译：本发明涉及应用免疫技术和医学领域。更具体地说，涉及用于产生针对任意序列或多糖表位的抗体的DNA基序疫苗设计，糖基DNA基序疫苗设计和免疫原设计，特别是那些针对其抗原诱导抗体的抗原表位，例如那些HIV-1。本发明还涉及诱导强大的细胞和体液免疫的免疫原设计。

7. 发明公开

EP3052517A4 MOSAIC CONSERVED REGION HIV IMMUNOGENIC POLYPEPTIDES 有权转让
标题翻译： HIV-IMMUNOGEN-POLYPEPTID MIT KONSERVIERTEN MOSAIKREGIONEN
公开(公告)号：EP3052517A4
公开(公告)日：2017-07-26
申请号：EP14846993
申请日：2014-09-30
申请人： LOS ALAMOS NAT SECURITY LLC , UNIV OXFORD INNOVATION LTD
发明人： KORBER BETTE T M , HANKE TOMAS , MCMICHAEL ANDREW
IPC分类号： C07K14/15 , A61K39/21
CPC分类号： A61K39/21 , A61K39/12 , C07K14/005 , C12N2740/16034
摘要： Disclosed herein are mosaic conserved region HIV polypeptides and immunogenic polypeptides including one or more of the mosaic conserved region polypeptides. In some embodiments, the immunogenic polypeptides are included in an immunogenic composition, such as a polyvalent immunogenic composition. Also disclosed herein are methods for treating or inhibiting HIV in a subject including administering one or more of the disclosed immunogenic polypeptides or compositions to a subject having or at risk of HIV infection. In some embodiments, the methods include inducing an immune response in a subject comprising administering to the subject at least one of the disclosed immunogenic polypeptides or a nucleic acid encoding at least one of the immunogenic polypeptides.
摘要翻译：本文公开了马赛克保守区HIV多肽和免疫原性多肽，包括一个或多个马赛克保守区多肽。在一些实施方案中，免疫原性多肽包含在免疫原性组合物中，例如多价免疫原性组合物。本文还公开了用于治疗或抑制受试者中的HIV的方法，其包括将一种或多种所公开的免疫原性多肽或组合物给予患有HIV感染或具有感染HIV风险的受试者。在一些实施方案中，所述方法包括在受试者中诱导免疫应答，包括向受试者施用至少一种所公开的免疫原性多肽或编码至少一种免疫原性多肽的核酸。

8. 发明公开

EP3187585A1 CMV GLYCOPROTEINS AND RECOMBINANT VECTORS 审中-公开
标题翻译： CMV糖蛋白和重组载体
公开(公告)号：EP3187585A1
公开(公告)日：2017-07-05
申请号：EP16200334.7
申请日：2011-03-25
申请人： Oregon Health & Science University
发明人： PICKER, Louis , FRUEH, Klaus , HANSEN, Scott G. , POWERS, Colin
IPC分类号： C12N15/38 , C12N15/86 , A61K39/245 , C12N7/00
CPC分类号： G01N33/56972 , A61K39/00 , A61K39/0011 , A61K39/02 , A61K39/12 , A61K39/21 , A61K39/245 , A61K2039/5254 , A61K2039/5256 , C07K14/005 , C12N7/00 , C12N15/86 , C12N2710/10343 , C12N2710/16121 , C12N2710/16122 , C12N2710/16131 , C12N2710/16134 , C12N2710/16143 , C12N2710/16162 , C12N2710/16171 , C12N2710/24143 , C12N2740/10034 , C12N2740/15034 , C12N2740/15043 , C12N2800/24
摘要： This invention also relates to recombinant vectors expressing one or more of the human CMV (HCMV) glycoproteins US2, US3, US6 and US 11 or corresponding functional rhesus CMV (RhCMV) homologues Rh182, Rh184, Rh185 or Rh189, methods of making them, uses for them, expression products from them, and uses for the expression products. This invention also relates to recombinant cytomegalovirus vectors vectors lacking one or more of the glycoproteins, methods of making them, uses for them, expression products from them, and uses for the expression products.
摘要翻译：本发明还涉及表达一种或多种人CMV（HCMV）糖蛋白US2，US3，US6和US11或相应的功能性恒河猴CMV（RhCMV）同源物Rh182，Rh184，Rh185或Rh189的重组载体，制备它们的方法，用途对他们来说，他们表达产品，并用于表达产品。本发明还涉及缺乏一种或多种糖蛋白的重组巨细胞病毒载体载体，制备它们的方法，它们的用途，来自它们的表达产物以及用于表达产物的用途。

9. 发明公开

EP3169787A1 HUMAN CYTOMEGALOVIRUS COMPRISING EXOGENOUS ANTIGENS 审中-公开
标题翻译：人类CYTOMEGALOVIRUS MIT外源抗原
公开(公告)号：EP3169787A1
公开(公告)日：2017-05-24
申请号：EP15745663.3
申请日：2015-07-16
申请人： Oregon Health & Science University
发明人： FRUEH, Klaus , HANSEN, Scott G. , NELSON, Jay , PICKER, Louis , CAPOSIO, Patrizia
IPC分类号： C12N15/86 , A61K39/00 , C07K14/16
CPC分类号： C12N15/86 , A61K39/12 , A61K39/21 , A61K2039/5254 , A61K2039/5256 , A61K2039/572 , C07K14/161 , C12N2710/16143 , C12N2740/15034 , C12N2740/16234
摘要： Human cytomegalovirus vectors comprising heterologous antigens are disclosed. The vectors derived from the TR strain, are ganciclovir-sensitive, include active US2, US3, US6, US7 and UL131A genes, and have a deleterious or inactivating mutation in the UL82 gene preventing the expression of pp71.
摘要翻译：公开了包含异源抗原的人巨细胞病毒载体。衍生自TR菌株的载体是更昔洛韦敏感性的，包括活性US2，US3，US6，US7和UL131A基因，并且在UL82基因中具有阻止pp71表达的有害或失活突变。

10. 发明授权

EP2290091B1 Recombinant measles viruses expressing epitopes of antigens of RNA viruses and use of the recombinant viruses for the preparation of vaccine compositions 无效
标题翻译：表达RNA病毒抗原表位的重组麻疹病毒和重组病毒用于制备疫苗组合物的用途
公开(公告)号：EP2290091B1
公开(公告)日：2017-05-10
申请号：EP10184907.3
申请日：2003-06-20
申请人： Institut Pasteur , Centre National de la Recherche Scientifique
发明人： Tangy, Frédéric , Lorin, Clarisse , Mollet, Lucile , Delebecque, Frédéric
IPC分类号： C12N15/86 , C12N7/00
CPC分类号： C12N15/86 , A61K39/12 , A61K39/165 , A61K39/21 , A61K47/6901 , A61K2039/5256 , C07K14/005 , C12N7/00 , C12N2740/16022 , C12N2740/16122 , C12N2760/18421 , C12N2760/18422 , C12N2760/18434 , C12N2760/18443 , C12N2760/18452 , C12N2770/24122 , Y02A50/388 , Y02A50/394
摘要： The invention relates to a recombinant measles virus expressing a heterologous amino acid sequence derived from an antigen of a determined RNA virus, said recombinant measles virus being capable of eliciting a humoral and/or a cellular immune response against measles virus or against said RNA virus or against both measles virus and against said RNA virus. It also relates to the use of said recombinant measles virus for the preparation of immunogenic composition.
摘要翻译：本发明涉及表达源自确定的RNA病毒的抗原的异源氨基酸序列的重组麻疹病毒，所述重组麻疹病毒能够引发针对麻疹病毒或针对所述RNA病毒的体液和/或细胞免疫应答，或针对麻疹病毒和针对所述RNA病毒。它还涉及所述重组麻疹病毒用于制备免疫原性组合物的用途。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式